Claims
- 1. A method of achieving hemolymphopoietic chimerism comprising:
administering to a recipient a bone seeking radiopharmaceutical; transplanting bone marrow-derived cells into the recipient; and transiently suppressing lymphocyte response so as to induce hemolymphopoietic chimerism.
- 2. The method according to claim 1, wherein the chimerism is induced so as to provide immunological tolerance.
- 3. The method of claim 2 wherein the immunological tolerance comprises tolerance to at least one member of the group consisting of alloantigens, autoantigens and xenoantigens.
- 4. The method according to claim 1, wherein the bone seeking radiopharmaceutical is a complex comprising a radionuclide and a ligand.
- 5. A method of claim 4 wherein the radionuclide is selected from the group consisting of Sm-153, Ho-166, Gd-159, Lu-177, Dy-165, Y-90, In-155m, Re-186, Re-188, Sn-117m, La-140,I-131, Cu-67, Ac-225, Bi-212, Bi-213, At-211, Ra-223, Pm-149, Rh-105; Au-198, Au-199, Dy-166, Sc-47, Yb-175, P-32, Sr-89, Ir-192, Th-149, and Ra-224.
- 6. A method of claim 4 wherein the ligand is selected from the group consisting of ethylenediaminetetramethylenephosphonic acid (EDTMP), diethylenetriaminepentamethylenephosphonic acid (DTPMP), hydroxyethylethylenediaminetrimethylenephosphonic acid (HEEDTMP), nitrilotrimethylenephosphonic acid (NTMP), tris(2-aminoethyl)aminehexamethylenephosphonic acid (TTHMP), 1-carboxyethylenediaminetetramethylenephosphonic acid (CEDTMP) and bis(aminoethylpiperazine)tetramethylenephosphonic acid (AEPTMP), Ethylenediaminetetraacetic acid (EDTA), 1,4,7,10-tetraazacyclododecane-N,N′,N″,N′″-tetramethylenephosphonic acid (DOTMP), hydroxyethyldiphosphonic acid (HEDP), methylenediphosphonic acid (MDP), diethylenetriaminepentaacetic acid (DTPA), hydroxethylethylenediaminetriacetic acid (HEDTA), and nitrilotriacetic acid (NTA).
- 7. The method according to claim 4 wherein the complex is selected from the group consisting of Sm-153-EDTMP, Sm-153-DOTMP, Ho-166-EDTMP, Ho-166-DOTMP, Gd-159-EDTMP, Gd-159-DOTMP, Dy-165-EDTMP, Dy-165-DOTMP, Re-186-HEDP, Re-188-HEDP, Sn-117m-DTPA.
- 8. The method according to claim 1 wherein the method of suppressing lymphocyte response comprises administering at least one biological modifier.
- 9. The method according to claim 8 wherein the biological modifier is an antibody, a cytokine, an immunosuppressive drug, a peptide, a protein, a nucleic acid or a combination thereof.
- 10. The method according to claim 8, wherein the biological modifier is at least one antibody that recognizes an antigen selected from the group consisting of CD154, CD4, CD8, CD3, CD5, CD55, CD40, CD40L, B7.1, B7.2, CD28, and LFA-1.
- 11. A method for decreasing rejection of transplanted organs, tissues or cells comprising:
administering to a recipient a bone seeking radiopharmaceutical; transplanting bone marrow-derived cells into the recipient; transiently suppressing lymphocyte response; and transplanting one or more organs, tissues or cells.
- 12. The method according to claim 11, wherein the bone seeking radiopharmaceutical is a complex comprising a radionuclide and a ligand.
- 13. The method of claim 12 wherein the radionuclide is selected from the group consisting of Sm-153, Ho-166, Gd-159, Lu-177, Dy-165, Y-90, In-155m, Re-186, Re-188, Sn-117m, La-140,I-131, Cu-67, Ac-225, Bi-212, Bi-213, At-211, Ra-223, Pm-149, Rh-105; Au-198, Au-199, Dy-166, Sc-47, Yb-175, P-32, Sr-89, Ir-192, Tb-149, and Ra-224.
- 14. The method of claim 12 wherein the ligand is selected from the group consisting of ethylenediaminetetramethylenephosphonic acid (EDTMP), diethylenetriaminepentamethylenephosphonic acid (DTPMP), hydroxyethylethylenediaminetrimethylenephosphonic acid (HEEDTMP), nitrilotrimethylenephosphonic acid (NTMP), tris(2-aminoethyl)aminehexamethylenephosphonic acid (TTHMP), 1-carboxyethylenediaminetetramethylenephosphonic acid (CEDTMP) and bis(aminoethylpiperazine)tetramethylenephosphonic acid (AEPTMP),. Ethylenediaminetetraacetic acid (EDTA), 1,4,7,10-tetraazacyclododecane-N,N′,N″,N′″-tetramethylenephosphonic acid (DOTMP), hydroxyethyldiphosphonic acid (HEDP), methylenediphosphonic acid (MDP), diethylenetriaminepentaacetic acid (DTPA), hydroxethylethylenediaminetriacetic acid (HEDTA), and nitrilotriacetic acid (NTA).
- 15. The method according to claim 12 wherein the complex is chosen from the group consisting of Sm-153-EDTMP, Sm-153-DOTMP, Ho-166-EDTMP, Ho-166-DOTMP, Gd-159-EDTMP, Gd-159-DOTMP, Dy-165-EDTMP, Dy-165-DOTMP, Re-186-HEDP, Re-188-HEDP, and Sn-117m-DTPA.
- 16. The method according to claim 11 wherein the method of suppressing lymphocyte response comprises administering at least one biological modifier.
- 17. The method according to claim 16 wherein the biological modifier is an antibody, a cytokine, an immunosuppressive drug, a peptide, a protein, a nucleic acid or a combination thereof.
- 18. The method according to claim 17, wherein the biological modifier is at least one antibody that recognizes an antigen selected from the group consisting of CD154, CD4, CD8, CD3, CD5, CD55, CD40, CD40L, B7.1, B7.2, CD28, and LFA-1.
- 19. The method according to claim 11 wherein the transplanted organ, tissue or cell comprises liver, heart, lung, kidney, intestine, pancreas, larynx, blood vessels limbs, endocrine organs, skin, islet cells, cornea, nerves, muscles, keratinocytes and keratynocyte precursors, chondrocytes and condrocyte precursors hepatocytes and hepatocyte precursors, myocytes and myoblasts including cardiomyocytes and cardiomyoblasts, neural cells and neural cell precursors, endothelial cells, endocrine cells and endocrine cell precursors, stem cells and cells of different lineage derived from stem cells.
- 20. A method for treating diabetes comprising the method of claim 19, wherein the transplanted cells are islet cells.
- 21. A method to treat autoimmune disease comprising:
administering to a recipient a bone seeking radiopharmaceutical; transplanting bone marrow-derived cells into the recipient; and transiently suppressing lymphocyte response.
- 22. The method of claim 21 wherein the transplanted bone marrow-derived is autologous and is either unmanipulated or is depleted of mature T-lymphocytes prior to transplantation.
- 23. The method according to claim 21, wherein the bone seeking radiopharmaceutical is a complex comprising a radionuclide and a ligand.
- 24. The method of claim 23 wherein the radionuclide is selected from the group consisting of Sm-153, Ho-166, Gd-159, Lu-177, Dy-165, Y-90, In-155m, Re-186, Re-188, Sn-117m, La-140,I-131, Cu-67, Ac-225, Bi-212, Bi-213, At-211, Ra-223, Pm-149, Rh-105; Au-198, Au-199, Dy-166, Sc-47, Yb-175, P-32, Sr-89, Ir-192, Tb-149, and Ra-224.
- 25. The method of claim 23 wherein the ligand is selected from the group consisting of ethylenediaminetetramethylenephosphonic acid (EDTMP), diethylenetriaminepentamethylenephosphonic acid (DTPMP), hydroxyethylethylenediaminetrimethylenephosphonic acid (HEEDTMP), nitrilotrimethylenephosphonic acid (NTMP), tris(2-aminoethyl)aminehexamethylenephosphonic acid (TTHMP), 1-carboxyethylenediaminetetramethylenephosphonic acid (CEDTMP) and bis(aminoethylpiperazine)tetramethylenephosphonic acid (AEPTMP),. Ethylenediaminetetraacetic acid (EDTA), 1,4,7,10-tetraazacyclododecane-N,N′,N″,N′″-tetramethylenephosphonic acid (DOTMP), hydroxyethyldiphosphonic acid (HEDP), methylenediphosphonic acid (MDP), diethylenetriaminepentaacetic acid (DTPA), hydroxethylethylenediaminetriacetic acid (HEDTA), and nitrilotriacetic acid (NTA).
- 26. The method according to claim 23 wherein the complex is chosen from the group consisting of Sm-153-EDTMP, Sm-153-DOTMP, Ho-166-EDTMP, Ho-166-DOTMP, Gd-159-EDTMP, Gd-159-DOTMP, Dy-165-EDTMP, Dy-165-DOTMP, Re-186-HEDP, Re-188-HEDP, and Sn-117m-DTPA.
- 27. The method according to claim 21 wherein the method of suppressing lymphocyte response comprises administering at least one biological modifier.
- 28. The method according to claim 27 wherein the biological modifier is an antibody, a cytokine, an immunosuppressive drug, a peptide, a protein, a nucleic acid or a combination thereof.
- 29. The method according to claim 28, wherein the biological modifier is at least one antibody that recognizes an antigen selected from the group consisting of CD154, CD4, CD8, CD3, CD5, CD55, CD40, CD40L, B7.1, B7.2, CD28, and LFA-1.
- 30. The method according to claim 21 wherein the autoimmune disease is selected from diseases of the nervous system, the eye, cardiac system, respiratory system, urogenital system, gastrointestinal system, blood, blood vessels, endocrine glands, skin, and musculoskeletal system.
- 31. The method according to claim 30 wherein the autoimmune disease is selected from rheumatoid arthritis, ankylosing spondilytis polymyositis, dermatomyositis systemic lupus erythematosus, vasculitides, Goodpasture's syndrome, Wegener granulomatosis uveitis, Sjogren's syndrome, Bechet's disease, autoimmune myocarditis and perycarditis, multiple sclerosis, inflammatory bowel disease, Crohn's disease, ulcerative colitis, autoimmune gastritis, autoimmune hepatitis primary biliary chirrosis, diabetes, autoimmune thyroid disease, Graves disease, Hashimoto thyroiditis, Addison's disease, ipoparathyroidism, autoimmune hypophysitis, ovaritis, myastenia gravis, alopecia areata universalis, vitiligo, psoriasispemphigus p, p scleroderma, and autoimmune diseases of the blood.
Parent Case Info
[0001] This application is a continuation-in-part of U.S. application Ser. No. 10/166,053, filed Jun. 11, 2002.
Continuation in Parts (1)
|
Number |
Date |
Country |
Parent |
10166053 |
Jun 2002 |
US |
Child |
10316790 |
Dec 2002 |
US |